tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Shea, 8 are a BUY (100%).
Analyst Matthew Shea, currently employed at NEEDHAM, carries an average stock price target met ratio of 80.56% that have a potential upside of 38.87% achieved within 74 days.
Matthew Shea’s has documented 16 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TOI, Oncology Institute at 17-Jun-2026.
Analyst best performing recommendations are on PRVA (PRIVIA HEALTH GROUP).
The best stock recommendation documented was for TOI (ONCOLOGY INSTITUTE) at 3/9/2026. The price target of $5 was fulfilled within 91 days with a profit of $2.27 (83.15%) receiving and performance score of 9.14.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 15-Nov-2016
$5
$1.05 (26.58%)
$14
Buy Since 22-Apr-2024
$6.75
$2.8 (70.89%)
$5.5
Buy Since 06-Jan-2016
$7
$3.05 (77.22%)
$6
Buy Since 23-Aug-2024
$7
$3.05 (77.22%)
$7
Buy Since 10-Jan-2025
$5
$1.05 (26.58%)
$4
Which stock is Matthew Shea is most bullish on?
Which stock is Matthew Shea is most reserved on?
What Year was the first public recommendation made by Matthew Shea?
